About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a company based in Rockville (United States) founded in 2005.. The company has 674 employees as of December 31, 2024. Supernus Pharmaceuticals has completed 3 acquisitions, including Adamas Pharma, Biscayne Pharma and SAGE Therapeutics. Supernus Pharmaceuticals offers products and services including QELBREE. Supernus Pharmaceuticals operates in a competitive market with competitors including Alto Neuroscience, Newron Pharmaceuticals, Neurovance, Seaport Therapeutics and Pasithea, among others.
- Headquarter Rockville, United States
- Employees 674 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Supernus Pharmaceuticals, Inc.
-
Annual Revenue
$661.82 M8.94as on Dec 31, 2024
-
Net Profit
$73.86 M5512.84as on Dec 31, 2024
-
EBITDA
$141.77 M44.28as on Dec 31, 2024
-
Latest Funding Round
$30 M (USD), Post-IPO
Jul 09, 2014
-
Investors
HealthCare Royalty Partners
& 1 more
-
Employee Count
674
as on Dec 31, 2024
-
Investments & Acquisitions
Adamas Pharma
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Supernus Pharmaceuticals
Supernus Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol SUPN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Supernus Pharmaceuticals
Supernus Pharmaceuticals offers a comprehensive portfolio of products and services, including QELBREE. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Approved treatment for central nervous system disorders
Unlock access to complete
Unlock access to complete
Sales and Marketing
160 people
Leadership Team
51 people
Product Management Team
14 people
Senior Team
14 people
Software Development Team
10 people
Operations Team
7 people
Finance and Accounting
7 people
Human Resources and Administration
5 people
Unlock access to complete
Funding Insights of Supernus Pharmaceuticals
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $30.0M
-
First Round
First Round
(26 Jun 2012)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2014 | Amount | Post-IPO - Supernus Pharmaceuticals | Valuation |
investors |
|
| Jun, 2012 | Amount | Grant - Supernus Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Supernus Pharmaceuticals
Supernus Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HealthCare Royalty Partners and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Supernus Pharmaceuticals
Supernus Pharmaceuticals has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Adamas Pharma, Biscayne Pharma and SAGE Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Clinical-stage drugs for CNS disorders and drug-resistant cancers are developed.
|
2012 | ||||
|
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
2002 | ||||
|
Developer of drug candidates for the treatment of rare CNS disorders
|
1971 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Supernus Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Supernus Pharmaceuticals Comparisons
Competitors of Supernus Pharmaceuticals
Supernus Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Newron Pharmaceuticals, Neurovance, Seaport Therapeutics and Pasithea, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| domain | founded_year | HQ Location |
Therapies for central nervous system diseases and pain are developed.
|
|
| domain | founded_year | HQ Location |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
|
| domain | founded_year | HQ Location |
Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology.
|
|
| domain | founded_year | HQ Location |
Pasithea is focused on developing treatments for neurological disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Supernus Pharmaceuticals
Frequently Asked Questions about Supernus Pharmaceuticals
When was Supernus Pharmaceuticals founded?
Supernus Pharmaceuticals was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Where is Supernus Pharmaceuticals located?
Supernus Pharmaceuticals is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Who is the current CEO of Supernus Pharmaceuticals?
Jack Khattar is the current CEO of Supernus Pharmaceuticals.
How many employees does Supernus Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Supernus Pharmaceuticals is 674.
What is the annual revenue of Supernus Pharmaceuticals?
Annual revenue of Supernus Pharmaceuticals is $661.82M as on Dec 31, 2024.
What does Supernus Pharmaceuticals do?
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, United States. Operations center on the development and commercialization of treatments for central nervous system diseases. Key products, such as Oxtellar and Trokendi, address epilepsy. The psychiatry pipeline features SPN-810 for impulsive aggression, SPN-812 for ADHD, and SPN-809 for depression. An acquisition of its parent company, Shrine Labs, occurred in late 2005.
Who are the top competitors of Supernus Pharmaceuticals?
Supernus Pharmaceuticals's top competitors include Alto Neuroscience, Newron Pharmaceuticals and Seaport Therapeutics.
What products or services does Supernus Pharmaceuticals offer?
Supernus Pharmaceuticals offers QELBREE.
Is Supernus Pharmaceuticals publicly traded?
Yes, Supernus Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol SUPN.
How many acquisitions has Supernus Pharmaceuticals made?
Supernus Pharmaceuticals has made 3 acquisitions, including Adamas Pharma, Biscayne Pharma, and SAGE Therapeutics.
Who are Supernus Pharmaceuticals's investors?
Supernus Pharmaceuticals has 2 investors. Key investors include HealthCare Royalty Partners, and HHS.
What is Supernus Pharmaceuticals's ticker symbol?
The ticker symbol of Supernus Pharmaceuticals is SUPN on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.